(Reuters) - The Food and Drug Administration warned on Tuesday that the antibiotic azithromycin, sold as Zithromax, can cause a potentially fatal irregular heart rhythm in some patients.
A study in the New England Journal of Medicine last May compared the risk of cardiovascular death from different antibacterial drugs and found that the drug, which is made by Pfizer Inc and is also sold by generic drugmakers, had a higher rate of death.
In its warning, the
FDA said the drug can cause abnormal changes in the electrical activity
of the heart that may lead to a potentially fatal heart rhythm known as prolonged QT interval, in which the timing of the heart's contractions becomes irregular.
The FDA said
doctors should use caution when giving the popular antibiotic to
patients known to have this condition or who have certain risk factors.
Those who may be at risk include people with low levels of potassium or
magnesium, a slower than normal heart rate, or people who take certain drugs used to treat abnormal heart rhythms, or arrhythmias. The drug could also cause problems in people with torsades de pointes, a specific, rare heart rhythm abnormality.
However, the FDA noted that other drugs in the same
class as azithromycin known as macrolides also have the potential for
causing QT prolongation, as do non-macrolide antibiotics, such as
fluoroquinolones, and doctors need to consider all of these risks when
choosing an antibiotic.
Pfizer officials were not immediately available for comment.
Shares of Pfizer were down 0.5 percent at $28.10 on Tuesday morning on the New York Stock Exchange.
(Reporting by Caroline Humer in New York and Julie
Steenhuysen in Chicago; editing by Gerald E. McCormick and Matthew
Lewis)
